Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + rituximab in Waldenström macroglobulinemia
2022-500574-34-00Phase 2Authorised
- Sponsor
- University Hospital Ulm
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of venetoclax and rituximab in Waldenström macroglobulinemia (WM) (2 arms), sponsored by University Hospital Ulm. Primary endpoint: Complete remission or very good partial remission rate at 12 months. Planned start Mar 2025; status: authorised.
02
Drugs
venetoclaxrituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2022-500574-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500574-34-00.